Processa Pharmaceuticals, Inc. (PCSA) stock
Close on Nov 13, 2026Market cap $5.20MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $5.20M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$193.16M
- EPS, diluted
- -$65.51
- Book value per share
- -$60.99
- Diluted shares
- 3M
Trading
- Previous close
- $1.84
- Open
- $1.86
- Day's range
- $1.80 – $1.91
- Volume
- 18,737
- Average volume (20 days)
- 26,219
- Beta (5 years)
- 0.80
- 52-week range
- $1.04 – $8.88
- RSI (14 days)
- 51.3
- Volatility (1 year)
- 174.8%
- Relative volume
- 0.09×
- WACC
- 9.1%
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | PCSA | S&P 500 | Difference | PCSA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +5.1% | -3.0% | +8.1 pts | ||
| 3 months | -25.6% | -2.8% | −22.8 pts | ||
| Year to date | -35.4% | +11.5% | −46.9 pts | ||
| 1 year | -74.5% | +13.5% | −88.0 pts | ||
| 3 years | -99.0% | +77.7% | −176.7 pts | -78.6% | +21.1% |
| 5 years | -99.9% | +72.6% | −172.6 pts | -77.8% | +11.5% |
| 10 years | -100.0% | +308.2% | −408.1 pts | -53.5% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Processa Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- News
- News
About Processa Pharmaceuticals
Pharmaceutical Preparations
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing Next Generation Cancer therapies. The company identifies existing, widely used cancer treatments that exhibit high toxicity and treatment-limiting side effects, modifying their metabolism or distribution to improve safety and efficacy while lowering toxicity. Its oncology pipeline includes PCS6422 (NGC-Cap), an oral therapy combined with capecitabine currently evaluated for solid tumors such as advanced breast cancer, and PCS11T (NGC-Iri), an analog targeting solid tumors. In addition to its oncology pipeline, the company evaluates opportunities for non-oncology clinical assets, including PCS12852 for gastroparesis and PCS499 for primary glomerular diseases.
Company profile, executives and historyProcessa Pharmaceuticals stock: common questions
What is Processa Pharmaceuticals's stock price?
PCSA closed at $1.86 on Nov 13, 2026, up 1.09% on the day. Over the past 52 weeks it traded between $1.04 and $8.88.
What is Processa Pharmaceuticals's market cap?
Processa Pharmaceuticals was worth $5.20M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is PCSA's P/E ratio?
Processa Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$65.51), so it has no meaningful P/E ratio.
Does Processa Pharmaceuticals pay a dividend?
No. Processa Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has PCSA stock performed over the past year?
Including dividends, PCSA returned -74.5% over the past year, against +13.5% for the S&P 500.
Who are Processa Pharmaceuticals's competitors?
Companies most similar to Processa Pharmaceuticals by business, industry and size include PRLD, ALLR, APRE, NCNA, TNGX.
See a number that looks wrong?